Sinclair's Esthetics Evolution
This article was originally published in Scrip
Sinclair IS Pharma Plc. has completed the strategic disposal of its non-esthetics business to Alliance Pharma Plc. for a total of £132m upfront in cash along with sales-related royalty payments relating to burn infection product Flammacerium US.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.